NCT00413478View on ClinicalTrials.gov

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Chronic Lymphocytic LeukemiaLeukemia
Interventions
DRUG

5-Azacytidine

Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER